Transcranial Blood–Brain Barrier Opening in Alzheimer's Disease Patients Using a Portable Focused Ultrasound System with Real-Time 2-D Cavitation Mapping

4 Sua Bae^{1†}, Keyu Liu^{1†}, Antonios N. Pouliopoulos^{1†}, Robin Ji¹, Sergio Jiménez-Gambín¹, Omid Yousefian¹,

5 Alina R. Kline-Schoder¹, Alec J. Batts¹, Fotios N. Tsitsos¹, Danae Kokossis², Akiva Mintz³, Lawrence S.

6 Honig⁴, and Elisa E. Konofagou^{1,3*}

7 [†]These authors contributed equally to this work.

8 Abstract

9 Background: Focused ultrasound (FUS) in combination with microbubbles has recently shown great 10 promise in facilitating blood-brain barrier (BBB) opening for drug delivery and immunotherapy in 11 Alzheimer's disease (AD). However, it is currently limited to systems integrated within the MRI 12 suites or requiring post-surgical implants, thus restricting its widespread clinical adoption. In this 13 pilot study, we investigate the clinical safety and feasibility of a portable, non-invasive 14 neuronavigation-guided FUS (NgFUS) system with integrated real-time 2-D microbubble cavitation 15 mapping.

16 *Methods*: A phase 1 clinical study with mild to moderate AD patients (N=6) underwent a single 17 session of microbubble-mediated NgFUS to induce transient BBB opening (BBBO). Microbubble 18 activity under FUS was monitored with real-time 2-D cavitation maps and dosing to ensure the 19 efficacy and safety of the NgFUS treatment. Post-operative MRI was used for BBB opening and 20 closure confirmation as well as safety assessment. Changes in AD biomarker levels in both blood 21 serum and extracellular vesicles (EVs) were evaluated, while changes in amyloid-beta (A β) load in 22 the brain were assessed through ¹⁸F-Florbetapir PET.

Results: BBBO was achieved in 5 out of 6 subjects with an average volume of 983 ± 626 mm³ following FUS at the right frontal lobe both in white and gray matter regions. The outpatient treatment was completed within 34.8 ± 10.7 min. Cavitation dose significantly correlated with the BBBO volume ($R^2>0.9$, N=4), demonstrating the portable NgFUS system's capability of predicting opening volumes. The cavitation maps co-localized closely with the BBBO location, representing the first report of real-time transcranial 2-D cavitation mapping in the human brain. Larger opening

29 volumes correlated with increased levels of AD biomarkers, including A β 42 (R^2 =0.74), Tau 30 $(R^2=0.95)$, and P-Tau181 ($R^2=0.86$), assayed in serum-derived EVs sampled 3 days after FUS (N=5). From PET scans, subjects showed a lower AB load increase in the treated frontal lobe region 31 32 compared to the contralateral region. Reduction in asymmetry standardized uptake value ratios 33 (SUVR) correlated with the cavitation dose ($R^2 > 0.9$, N=3). Clinical changes in the mini-mental state 34 examination over 6 months were within the expected range of cognitive decline with no additional 35 changes observed as a result of FUS. 36 *Conclusion*: We showed the safety and feasibility of this cost-effective and time-efficient portable 37 NgFUS treatment for BBBO in AD patients with the first demonstration of real-time 2-D cavitation 38 mapping. The cavitation dose correlated with BBBO volume, a slowed increase in pathology, and 39 serum detection of AD proteins. Our study highlights the potential for accessible FUS treatment in 40 AD, with or without drug delivery.

41 Keywords: Alzheimer's disease; blood-brain barrier; focused ultrasound; microbubbles; cavitation
42 mapping;

43

44 **Author affiliations**:

¹Department of Biomedical Engineering, Columbia University, New York, NY 10032, USA

²Department of Radiation Oncology, Columbia University Irving Medical Center, New York, NY
10032, USA

⁴⁸ ³Department of Radiology, Columbia University Irving Medical Center, New York, NY 10032, USA

⁴Department of Neurology and Taub Institute, Columbia University Irving Medical Center 10032,

- 50 New York, NY, USA
- 51 Correspondence to: Sua Bae, Elisa E. Konofagou
- 52 Full address: 630 West 168th Street, New York, NY 10032, USA
- 53 E-mail: sb4495@columbia.edu, ek2191@columbia.edu

55 Main Text

56 Introduction

57 Alzheimer's disease (AD) is the most common neurodegenerative disorder, typically with 58 progressive amnestic cognitive impairment, and its prevalence increases with the aged population 59 growth [1]. Only since 2021 have effective disease-modifying treatments been available for Alzheimer's disease. Currently, three monoclonal antibodies against amyloid-beta (Aβ) have been 60 61 shown to be effective: aducanumab [2], lecanemab [3], and donanemab [4]. Clinical studies have 62 demonstrated that administration of these antibodies markedly reduces the amount of Aβ-containing 63 cerebral neuritic plaques, and the latter two antibodies have been proven to slow the clinical decline. 64 However, these antibodies do have limitations, including only limited slowing of cognitive decline 65 and cerebral side effects, such as amyloid-related imaging abnormalities of edema/effusion and hemorrhage. Anti-Aß monoclonal antibodies bind to different forms of Aß and promote clearance 66 67 of plaques from the brain. However, for most, but not all, antibodies, the blood-brain barrier (BBB) 68 poses a challenge to their use because only a small proportion of the administered drug is able to 69 enter the brain, which affects their effectiveness in terms of dosage, frequency, and duration of 70 treatment [5,6]. Although direct intracerebral infusion could possibly circumvent the BBB 71 restriction, this invasive procedure entails risks [7].

72 Transient BBB opening by microbubble-mediated focused ultrasound (FUS) is a promising non-73 invasive therapy for enhancing BBB permeability, thereby facilitating the delivery of therapeutic 74 drugs or promoting immune responses without the use of drugs [8–10]. In this treatment, 75 microbubbles are systemically administered while FUS induces the rapid oscillation of 76 microbubbles, called cavitation, at a targeted volume in the brain (Figure 1). Precise FUS treatment 77 can induce local and transient BBB opening (BBBO) and promote immune response [11,12]. 78 Numerous preclinical studies have proven that BBBO can lead to a decrease in A β or tau proteins in 79 the brain and the cognitive improvement with and without drugs by increased immune response such 80 as microglial phagocytosis [13–15].

Many clinical trials have demonstrated that magnetic resonance (MR)-guided focused ultrasound (MRgFUS) can safely and transiently open BBB in patients with AD [16–19], amyotrophic lateral sclerosis [20], Parkinson's disease [21], glioma [22,23], and brain metastases [24]. Previous studies with AD patients have shown that BBBO induces a modest reduction in ¹⁸F-Florbetaben uptake ratio

in PET with no cognitive worsening after multiple sessions of MRgFUS treatment [16-19,25]. A 85 86 recent study utilizing MRgFUS reported that monthly BBBO treatment combined with aducanumab 87 infusion led to a substantial reduction in $A\beta$ levels in three patients over six months, as measured by PET [26]. While MRgFUS is the most widely used approach for clinical trials of BBBO, it generally 88 89 requires the patient to stay still with their heads fixed by a stereotaxic frame in the MR scanner for 90 a few hours. Alternatively, an implantable FUS device has been utilized in clinical trials, 91 demonstrating a non-significant reduction in amyloid based on ¹⁸F-Florbetapir PET scans after 92 multiple treatments [27]. Although this approach has been proven well-tolerated, it requires a burr 93 hole achieved with brain surgery, making it invasive. The invasiveness of the procedure makes it a 94 less preferred option for treating Alzheimer's disease, particularly given that the typical patient 95 population is older and may have multiple comorbidities.

Given the need for repetitive treatments and the advanced age of Alzheimer's disease patients, there is a compelling demand for facilitating a low-cost and non-invasive treatment approach. Portable neuronavigation-guided FUS (NgFUS) systems can provide FUS treatment outside an MR scanner in an outpatient room. Portable systems have been employed in both preclinical and clinical studies [28–31], but only one clinical study has been reported in the context of Alzheimer's disease, showing modest cognitive improvement after FUS [28]. However, this study did not induce BBBO or investigate if there were any changes in amyloid or tau protein load.

103 In this Phase 1 clinical study (NCT04118764), we assessed the clinical feasibility and safety of 104 BBBO in six subjects with mild-to-moderate Alzheimer's disease using a portable FUS system that 105 we developed and verified in preclinical studies [32–34]. A single 2-minute FUS sonication session 106 was performed per subject without a stereotaxic frame or a MR scanner. Real-time cavitation 107 monitoring was employed to measure the treatment dose and assess its capability of predicting 108 BBBO volume in the human brain. To our knowledge, this is the first report of real-time cavitation 109 mapping in the human brain using a portable FUS system. Neurological and biological effects of the 110 portable FUS system were evaluated by blood biomarker analysis, ¹⁸F-Florbetapir PET scans, and 111 mini-mental state examination (MMSE).

- 112
- 113 **Results**
- 114 Study Overview

115 The primary objective of the study is to assess the safety and feasibility of FUS-induced BBBO in 116 Alzheimer's disease patients, using a portable, noninvasive FUS system. Secondary objectives includes testing the feasibility of cavitation mapping and observing changes in ¹⁸F-Florbetapir PET 117 118 and in blood biomarkers. Six Alzheimer's disease patients $(2M/4F, age = 69.7 \pm 7.2 \text{ yr})$ were enrolled 119 in a phase 1 trial under FDA and Columbia University IRB approval (NCT04118764) (Table 1). 120 Inclusion and exclusion criteria, including diagnosis of Alzheimer's disease, amyloid positivity on 121 ¹⁸F-Florbetapir PET scan, and an MMSE score between 12 and 26, are listed in Table S1. Figure 2 122 presents the timeline of the clinical trial. All subjects underwent one session of FUS sonication and 123 had pre- and post-treatment scans, blood tests, and MMSE assessments.

124 Portable NgFUS system allowed for efficient BBBO

125 The target location was selected in a PET amyloid-positive region of the right frontal lobe, and the 126 FUS trajectory was determined by considering the beam incidence angle relative to the skull (Figure 127 3A). Skull insertion loss (i.e., attenuation), obtained from patient-specific acoustic simulations 128 (Figure 3B) and shown in Table 2, allowed us to adjust the sonication power to deliver a derated in 129 situ peak-negative pressure of 200 kPa. On the day of treatment, all subjects received a single FUS 130 treatment with microbubble administration (0.1 mL/kg) using the portable NgFUS system, while 131 seated in a medical recliner chair in an outpatient unit (Figure 3C). This process was guided by 132 neuronavigation (Figure 3D) and monitored by cavitation dose and mapping (Figure 3E). FUS was 133 deployed through a contact area with a diameter of less than 50 mm, which allowed for partial hair 134 shaving instead of complete head shaving (Figure S1). All sessions were uneventful and the average 135 treatment procedure time was 34.8±10.7 min.

136 Five subjects underwent successful BBBO at the treated location in the frontal lobe as evidenced by 137 post-FUS T1-weighted MRI (Figure 4A), and the quantified contrast-enhanced volume, which serves as a measure of BBBO volume, was 983±626 mm³ (Figure 4C and 4D and Table 2). One 138 139 participant (subject 3) had no detectable opening (Figure S2), likely due to inadequate microbubble 140 administration caused by a syringe malfunction and patient movement resulting from not using the 141 head and chin rest. Subject 1 exhibited the largest opening volume of 2,013 mm³, which extended 142 to the left thalamus beyond the lateral ventricles while subject 4 exhibited the smallest opening volume of 278 mm³. All of the openings from the 5 subjects were closed within 72 h, which was 143 144 confirmed by the follow-up scans on day 3 (Figure 4B). The opening and closing of the BBB were

145 confirmed by a neuro-radiologist, and the BBBO was quantified from the subtracted contrast-146 enhanced T1-weighted MRI, as described in the Materials and Methods section.

147 Safety evaluation

148 There were no serious adverse events (SAEs) and no clinical changes after the treatments. One 149 subject (subject 1) had an adverse event (AE) including both mild skin erythema on day 0 (resolved 150 within 3 days) and asymptomatic cerebral edema with a superficial hemorrhagic component on day 151 3. MRI images showed an area of T2 fluid-attenuated inversion recovery (FLAIR) hyper-intensity 152 on day 3, most intense at the cortical targeted location but extending deeper (Figure S3), with 153 susceptibility-weighted imaging (SWI) hypo-intensity superficially within the same region (Figure 154 S4). The subject was asymptomatic and the MRI abnormalities were all resolved in follow-up scans 155 on day 15. Other subjects did not show abnormalities in the safety MR scans 3 days after the 156 treatment.

157 Cavitation dose and map showed promising results for predicting the BBBO

To monitor the safety and efficacy of the treatment, cavitation signal during sonication was observed.
Passive cavitation detection (PCD) with a single-element transducer was utilized to obtain cavitation
dose (CD) for subjects 1–4, while passive acoustic mapping (PAM) with a imaging array transducer
was employed for subjects 5 and 6 to obtain the 2-D cavitation maps.

162 Figures 5A–5C show the real-time cavitation dose monitoring results from subjects 1–4. For subjects 163 1, 2, and 4, ultraharmonic and broadband CDs increased after the microbubble injection (t = 20-30164 s) and persisted until the end of the sonication (t = 120 s), indicating the cavitation activity of the 165 injected microbubbles (Figure 5A). On the other hand, for subject 3 which exhibited no detectable 166 opening, the increased CD was not sustained over time, resulting in a low cumulative CD (CCD). 167 The low cavitation energy for subject 3 is also evident in the spectrogram (Figure 5B). Across the four subjects, the higher CCDs were detected with increasing BBBO volume (Figure 5C), resulting 168 in strong positive linear correlations ($R^2 > 0.9$, p < 0.05). 169

Figures 5D and 5E depict the real-time 2-D cavitation maps obtained by PAM and their corresponding BBBO regions in MRI, respectively, from subjects 5 and 6. To our knowledge, this is the first demonstration of 2-D transcranial PAM in the human brain. The cavitation map that shows the spatial distribution of acoustic energy detected from microbubble activity (Figure 5D) roughly

174 matched with the BBBO location (Figure 5E); both the acoustic energy and BBBO locations were 175 shifted to the left side of the focus in subject 5, and aligned with the focus in subject 6. Compared to 176 subject 5, subject 6 showed approximately 12 dB higher averaged acoustic energy in the map and exhibited a larger opening (278 mm³ vs. 1262 mm³). From the pixel-wise correlation analysis 177 178 between the PAM cavitation map and the BBBO volume observed in MRI, the area under the curve 179 (AUC) of the receiver operating characteristic (ROC) and precision-recall (PR) curves were 180 AUC_{ROC}=0.8 and AUC_{PR}=0.7, respectively, showing the potential of PAM for predicting BBBO 181 volume.

182 Elevated blood biomarker levels correlated with BBBO size

183 Both serum and serum-derived extracellular vesicle (EV) levels of biomarkers 3 days after FUS were 184 compared with the baseline levels obtained 1–2 hours prior to NgFUS for subjects 2–6. Subject 1's 185 biomarker levels were not obtained due to improper handling of the blood specimen and were 186 excluded from the analysis. Figure 6 shows the correlation between BBBO volume and biomarker 187 levels for S100 β in serum, and A β 42, A β 42/A β 40, GFAP, Tau, and pT181 in EVs. Subjects with 188 larger opening volumes displayed elevated serum levels of S100 calcium-binding protein β (S100 β) 189 (p < 0.05), indicating compromised BBB integrity [35] (Figure 6A). Furthermore, we identified 190 several statistically-significant positive linear relationships between the opening size and the serum-191 derived EV levels of Alzheimer's disease-related proteins, while such relationships were not 192 observed with serum biomarker levels. Notably, glial fibrillary acidic protein (GFAP), Tau, and 193 phosphorylated-Tau 181 (pT181) fold-changes exhibited significant linear correlations (p < 0.05) 194 (Figure 6D–6F), while the correlations for A β 42 (p = 0.062) and the A β 42/A β 40 ratio (p = 0.096) 195 were not statistically significant (Figure 6B and 6C). There were no significant group-wise changes 196 possibly due to the large variation in BBBO volume (Figure S5).

197 A modest decrease in asymmetry SUVR correlated with the size of BBBO and

198 cavitation dose

Figure 7 shows the percent changes in standard uptake value ratio (SUVR) or asymmetry SUVR of
 ¹⁸F-Florbetapir compared to the baseline. Subject 3 was excluded due to the absence of BBBO.
 Although there was no group-wise reduction in SUVR (Figure 7A–7C, Table 3), all subjects with
 BBBO showed a modest reduction in asymmetry SUVR which assesses the SUVR in the treated

203 region compared to that of the contralateral region (Figure 7D–7F, Table 3). Specifically, asymmetry 204 values decreased by $1.47\pm0.77\%$ (p=0.013) in the frontal lobe and by $0.90\pm0.26\%$ (p=0.001) in the 205 hemisphere at the 2nd follow-up compared to the baseline. A non-significant linear relationship 206 $(R^2=0.69, p=0.08)$ was measured between the BBBO volume and the 1st follow-up asymmetry 207 changes within the respective volumes (Figure 7G). A relationship of the asymmetry SUVR change 208 with CD was analyzed among subjects who exhibited BBBO with cavitation monitoring using a 209 single-element detector (subjects 1, 2 and 4). Although negative linear relationships were observed 210 between the 1st follow-up asymmetry changes and the CCDs (Figure 7H), these results should be 211 interpreted with caution due to the small sample size (Figure 7H). Changes in SUVR and asymmetry 212 values for each subject are listed in Table S2 and PET images are presented in Figure S2. SUVR 213 Changes in Centiloid units are shown in Figure S6 to enable standardized comparison with other 214 studies.

215 A single BBBO treatment did not significantly alter cognitive function

Comparing the baseline scores, the MMSE score decreased by 1.80 ± 2.71 among the five subjects with BBBO and by 2.50 ± 2.93 among all six enrolled subjects, approximately 3 months after NgFUS. When compared with the Alzheimer's disease neuroimaging initiative (ADNI) database, subjects with successful BBBO did not exhibit statistically different changes in MMSE over a similar time frame (p > 0.45), indicating no cognitive changes due to FUS-induced BBBO (Table S3). Individual MMSE scores are listed in Table S4.

222 Targeting accuracy and precision

223 Targeting of the FUS transducer during treatment was performed using a manual arm. The distance 224 and angular errors of manual transducer positioning were 5.7 ± 1.4 mm and $11.2\pm2.5^{\circ}$, respectively. 225 Mean absolute deviation and maximum distance of the subject motion during the 2-min treatment 226 were 0.3 ± 0.1 and 1.2 ± 0.2 mm when using a head and chin rest (subjects 4–6), and 2.3 mm and 9.4 227 mm without using the rest (subject 3) (Figure S7, Table 2). Distance between the centroid of the 228 BBBO and the simulated focus was 12.3±6.1 mm, mostly along the FUS trajectory. There was no 229 consistent trend in the shift towards or away from the transducer, as it depended on the skull 230 properties and the selected treatment location for each subject.

232 **Discussion**

233 In this pilot study, we demonstrated the feasibility and safety of the portable FUS system with 234 cavitation monitoring for BBB permeability enhancement at the right frontal lobe in six Alzheimer's 235 disease patients. Five out of six subjects underwent localized BBBO which resolved within 72 h. 236 One AE occurred and resolved in 15 days, and no SAE was reported. No clinically significant 237 changes were observed in SUVR or cognitive test scores after FUS; however, the asymmetry SUVR 238 reduced modestly and exhibited a linear correlation with the BBBO volume. The CD demonstrated 239 correlations with the BBBO volume, blood biomarker level increase, and the asymmetry SUVR 240 decrease, proving the potential benefits of integrated cavitation monitoring to predict treatment 241 outcomes.

242 In clinical studies using MRgFUS, acoustic cavitation dose maps were generated by sonicating 243 dozens of subspots and mapping the measured cavitation dose to each subspot, assuming that the 244 received cavitation signals originated only from the focus, neglecting off-site cavitation [23,24,36]. 245 In contrast, our portable FUS system provides a real-time 2-D cavitation map, offering not only off-246 target cavitation imaging but also a more precise estimation of CD localized at the target. To our 247 knowledge, this is the first demonstration of 2-D PAM cavitation maps being obtained in the human 248 brain during BBBO. Cavitation mapping holds significant potential for enhancing both the safety 249 and efficacy of future treatments. By providing real-time visualization of cavitation activity, this 250 technology enables clinicians to immediately identify and mitigate any off-target effects, reducing 251 the risk of unintended damage to surrounding tissues. Furthermore, improved accuracy in estimating 252 the CD could result in more predictable and effective BBBO.

253 Although we aimed to deliver the same acoustic pressure at the brain target, the BBBO size varied 254 among the subjects from 278 mm³ to 2013 mm³. This variability could be attributed to the challenges in estimation of skull-induced attenuation, which determined the FUS transmit power. The 255 256 attenuation estimates may have been affected by CT-MR registration errors in the acoustic 257 simulation (5–10 mm in distance and $1-16^{\circ}$ in angle) that we identified at the conclusion of the trial. 258 Another factor may lie in the transducer positioning errors which caused discrepancies between the 259 trajectory used for the simulation and the achieved trajectory during treatment (Table 2). Further 260 analysis of the pressure estimation errors is presented in the Supplementary Discussion. The re-261 estimated pressure map after correcting the errors and the trajectories showed higher acoustic energy

for larger opening cases (Figure S8A), with the most intense energy distribution in subject 1. The re-estimated maximum pressure in the brain (Table S5) showed a linear relationship ($R^2 = 0.84$) with the contrast-enhanced volume (Figure S8B), which may explain the variance in BBBO size across the subjects and the AE in subject 1.

266 Five subjects showed contrast enhancement within an ellipsoidal volume along the FUS beam 267 trajectory (Figure 4C and 4D, and Movie S1) consistent with the cigar-shaped focus (Figure S8A). 268 Although the FUS focal volume included more white matter (WM) than gray matter (GM), the 269 opening volume exhibited similar proportions of GM and WM (Figure S9). The higher probability 270 of opening in GM than in WM was reported in our previous non-human primate (NHP) studies 271 [33,37,38], where GM exhibited increased susceptibility to BBBO relative to WM, indicated by 272 increased contrast enhancement on T1-weighted MRI. In this study, notable sulcal enhancements in 273 GM were observed (Figure 4A and Figures S10A and S10B). Additionally, the non-uniformly 274 distributed opening within the focal volume may be explained by the regional difference in vascular 275 density and tissue property, or increased ultrasound attenuation [37,39–42].

276 In subject 4, the contrast enhancement on MRI was found not only along the FUS trajectory from 277 the superior frontal cortex to the cingulate cortex, but also along the cingulate sulcus in the anterior-278 posterior direction (indicated with white arrowheads in Figures 4A and 4C, and S9C). The sulcal 279 enhancement beyond the ellipsoidal focus might not indicate BBBO, because it extended 280 approximately 22 mm posterior from the focus while the focal size is only 6 mm wide. Instead, this 281 vessel-like extravasation of the contrast agent might have occurred through the vessel wall or the 282 perivascular space (PVS) that extends along the perforating vessels [43], indicating a potential 283 increase in permeability of the blood-meningeal barrier. A possible explanation might be that the 284 contrast agent entered the PVS through the disrupted BBB within the ellipsoidal focus and then 285 permeated posteriorly along the cingulate sulcus. This finding may be consistent not only with recent 286 preclinical studies on glymphatic clearance effect of microbubble-mediated FUS in rodents [44,45] 287 but also with clinical studies using MRgFUS [46,47]. These clinical studies also demonstrated 288 blood-meningeal barrier opening and glymphatic clearance in humans, reporting hyperintense linear 289 enhancement along the hippocampal fissure [47] and contrast accumulation in the subarachnoid 290 space at the frontal lobe [46] following BBBO.

291 The first possible reason for the BBBO failure in subject 3 is the delayed bolus injection of 292 compromised microbubbles due to the malfunction of the syringe/catheter system. The catheter was 293 blocked at the initial injection attempt, resulting in the pressurization inside the syringe and the 294 destruction of the microbubbles. Although the microbubble solution was eventually injected at t =295 20 s after the start of sonication, the increases in CDs were minimal compared to other subjects 296 (Figures 5A and 5B). The second reason could be attributed to subject movement. The head and chin 297 rest were not used for this subject, resulting in the medial movement of ~9 mm during the 2-min 298 sonication, which was approximately 6–10 times larger than those of other subjects (Figure S7 and 299 Table 2). The subject movement (i.e., movement of the focus) might have compromised the localized 300 acoustic energy delivered, as evidenced by the reduced CDs at t = 90 s coinciding with the sudden 301 movement (gray arrows in both Figure 5A and Figure S7A).

302 In this study, statistically significant relationships between the opening size and harmonic, 303 ultraharmonic, and broadband cavitation energies were detected (Figure 5C), consistent with our 304 preclinical studies with mice and NHPs [33,48,49]. A recent study with MRgFUS in humans also 305 showed the correlation between the subharmonic acoustic emission and the contrast-enhanced T1-306 weighted MR signal [23]. All subjects with BBBO showed overall increases in CD 20-30 s after the 307 microbubble bolus injection (Figures 5A and 5B), indicating the onset of microbubble cavitation 308 activity in the sonicated region. In some cases, the CD showed a high fluctuation before the major 309 increase (harmonic CD in subject 2 and ultraharmonic CD in subject 4) or did not increase even after 310 the flush (harmonic CD in subject 4). Compared to our preclinical studies with the same FUS 311 transducer [33,34] where flat CD was usually observed before the injection in NHPs fixed by a 312 stereotaxic frame, the baseline CD in this study was relatively unstable potentially due to motion. In 313 addition, fluctuations in CD can also result from tissues, small air-bubbles in the coupling gel, or the 314 membrane on the water cone [50]. The higher fluctuations observed in the harmonic and 315 ultraharmonic CD profiles can be attributed to the measurements based on peak amplitude, whereas 316 the broadband CD was determined by the averaged amplitude within a bandwidth. Additionally, 317 spectral leakage from narrowband (harmonic and ultraharmonic) signals into the broadband may 318 have occurred. An improved method for quantifying narrowband and broadband signals could be 319 employed in future studies [51].

Harmonic and ultraharmonic CDs are typically associated with stable cavitation, characterized bythe repetitive oscillation of microbubbles. Meanwhile, broadband CDs are more closely linked to

322 inertial cavitation, which occurs when microbubbles collapse, leading to more violent mechanical 323 effects. Due to these effects, monitoring of broadband CDs has been utilized to prevent tissue 324 damage in mice [52,53] and non-human primates [33]. Similarly, efforts have been made to 325 minimize the microbubble nonlinear behavior (i.e., subharmonic and ultraharmonic emissions) to 326 reduce the possibility of damage in rabbits [54,55]. In our clinical study, BBBO was achieved 327 without MRI-detectable damage in subjects 2 and 4, despite a 10–20 dB increase in ultraharmonic 328 and broadband CDs observed. This suggests that not only stable but also stable-inertial and inertial 329 cavitation was likely involved in facilitating BBBO [9,56]. Further studies are warranted to establish 330 safe thresholds for ultraharmonic and broadband CD levels that effectively induce BBBO without 331 causing tissue damage.

332 The reduction in SUVR was less pronounced in our study than in previous studies using an 333 implantable FUS device [27] or using an MRgFUS system [16-19,26]. This difference may be 334 attributed to the fact that we conducted a single session of treatment, while the prior studies involved 335 2–7 treatment sessions with larger treatment volumes. Nevertheless, we found significant decreases 336 in asymmetry at the 2nd follow-up (Figure 7E and 7F), indicating a lower A β accumulation rate or 337 elimination of amyloid in the treated side compared to the contralateral side. These asymmetry 338 changes after FUS are consistent with findings from prior studies [16–19,25–27]. In addition, this 339 lowered asymmetry SUVR across the treated frontal lobe and the hemisphere demonstrates the 340 potential of FUS to exert holistic therapeutic effects beyond the treated region. When measured 341 within the BBBO volumes in GM and WM (Figure 7D), the asymmetry did not show an apparent 342 group-wise reduction possibly due to the small and variable BBBO volumes across the subjects. 343 However, they correlated with the FUS treatment characteristics (i.e., BBBO size and CCDs) 344 (Figures 7G and 7H). A larger BBBO or a higher harmonic CCD was related to the reduced $A\beta$ 345 accumulation in the treated region relative to the contralateral region. The observed decrease in 346 SUVR asymmetry may suggest the effectiveness of the targeted treatment, potentially indicating a 347 slowing or alteration in disease progression. Nevertheless, the small number of subjects in this pilot 348 study warrants further investigation with larger cohorts to confirm these preliminary findings.

Preclinical studies have reported improved cognitive function after FUS [14,57,58] and a clinical study using MRgFUS has shown a cognitive improvement measured by the caregiver-administered neuropsychiatric inventory (CGA-NPI) [17]. However, the majority of clinical studies so far have reported non-significant changes in cognitive improvement following FUS-induced BBBO,

examined by MMSE and ADAS-cog, evidencing no worsening of cognitive decline due to FUS
[16,18,19]. Our MMSE results are also consistent with these findings.

355 A previous MRgFUS study reported significant increases in CSF T-Tau and CSF and plasma 356 neurofilament light chain levels 1 week after MRgFUS and associated the increases with the T2* 357 hypointensity findings in two patients [19]. In our study, although no group-wise changes in 358 biomarker levels were found, the BBBO volume was significantly correlated with the increased EV 359 levels of GFAP, Tau and pTau-181, 3 days after NgFUS without any abnormalities in MRI. The 360 absence of a significant correlation between changes in A^β biomarker levels and BBBO volume 361 could be due to the small sample size or a weaker association with BBBO compared to other 362 biomarkers, given Meng et al.'s study, which also reported no significant changes in A β biomarker 363 levels [19]. The elevated levels of EV biomarkers indicate the release of proteins to the bloodstream 364 by FUS, consistent with sonobiopsy behavior noted in prior studies [59,60]. As the BBBO volume 365 also correlated with the reduced SUVR increase in the treated brain region, further investigation is 366 warranted to discover the potential of FUS for clearing Alzheimer's disease-related proteins from 367 the brain to the bloodstream. The overall increased correlation of BBBO volume with the proteins 368 in serum-derived EVs compared to serum levels alone indicates that EVs may be a more sensitive 369 diagnostic tool for biomarker detection as a result of FUS-mediated BBBO. Mitochondria or 370 endosome contamination was not accounted for in this study and may have influenced the absolute 371 biomarker levels. While this study captures biomarker changes at a single time-point, extending our 372 observations over multiple time-points would provide a more comprehensive understanding of 373 biomarker release attributed to FUS.

374 Despite the promising findings of the study reported herein, there are several limitations, including 375 a limited number of subjects, a single treatment at a single target location, inconsistency in BBBO 376 volume, and targeting errors. This was a single-arm phase I trial with only six subjects and no control 377 group. Despite the significant trends and differences observed in cavitation, biomarkers, and PET 378 analysis, the results of this study should be interpreted with caution due to the small number of 379 subjects. Furthermore, without a control group, the MMSE results might be influenced by placebo 380 effects and should be interpreted with caution. Additionally, since multiple treatments have proven 381 beneficial [26], evaluating the safety of regular NgFUS treatments is required. Future multi-arm 382 phase II/III trials will not only involve a larger number of subjects and incorporate sham groups but 383 will also include multiple NgFUS treatments to assess the safety of repeated sessions. Lastly, since

384 our study included only mild-to-moderate AD patients, our results may not necessarily be 385 generalizable to patients with lesser severity (pre-symptomatic), greater severity (severe disease), or 386 those with various medical comorbidities.

387 To achieve more consistent BBBO volume across subjects, precise transducer positioning and 388 accurate patient-specific simulations will be necessary in future studies. Based on our acoustic 389 simulations, maintaining a transducer positioning error less than 3-5 mm in distance and $4-6^{\circ}$ in 390 angle is required to ensure an error margin of less than 10% in in-situ pressure. Robotics with 391 neuronavigation guidance could be utilized to minimize manual positioning errors, while patient-392 specific fiducial markers could help reduce potential errors in registering the subject's head to a 393 virtual space. Moreover, we anticipate that the updated simulation pipeline will yield more accurate 394 skull-induced attenuation estimates, given the robust correlation observed between the re-estimated 395 attenuation and the resulting BBBO volume (Figure S8). Additionally, to further reduce inter-patient 396 variability, we plan to implement real-time closed-loop feedback controllers based on cavitation 397 metrics [61].

Furthermore, we plan to advance from our 2-D PAM to 3-D PAM using a matrix array probe, providing more comprehensive volumetric cavitation information. Additionally, we will further improve the mapping by employing skull-induced aberration correction.

401 Another limitation of our study is the small treated volume, considering that Alzheimer's disease 402 impacts broad regions of the brain [17,19]. To achieve more effective outcomes, our portable NgFUS 403 system could adopt a larger volume treatment approach by utilizing a robotic arm, similar to a pre-404 clinical study by Leinenga et al [13]. In addition, a subject-specific hologram lens could be employed 405 for a larger and constant focal size across subjects [62].

406 **Conclusions**

The study presented herein demonstrates the safety and feasibility of transient and non-invasive BBBO in patients with Alzheimer's disease using a portable NgFUS system. The BBBO volume showed linear correlations with the treatment dose (i.e., CCDs), the elevated level of biomarkers in serum-derived EVs, and the asymmetry SUVR changes. This low-cost and reliable technology may facilitate wider adoption of FUS treatment at the point of care for not only Alzheimer's disease but also for several other neurological disorders.

413 Materials and Methods

414 Study Design

415 This study was a phase 1 clinical trial (NCT04118764) of six subjects for evaluating the safety and 416 feasibility of NgFUS-mediated BBBO in patients diagnosed with mild-to-moderate Alzheimer's 417 disease. A power analysis prior to the trial showed that at least six subjects are needed to report a 418 result with a significance level of 0.05, a power of 0.95, and an effective size of 4 (e.g., to detect a difference before and after FUS with a volume of 200 mm³ with a standard deviation of 50 mm³). 419 420 The study was approved by the FDA and the Institutional Review Board (IRB) at Columbia 421 University. After providing informed consent, participant eligibility was determined by the 422 neurologist on the study based on the MRI and 18F-florbetapir PET scans, the participant and family 423 interview, and clinical scales including MMSE, geriatric depression scale (GDS), and modified 424 Hachinski ischemia scale (MHIS) (Table S1). Out of the ten subjects screened, four subjects were 425 excluded due to low MMSE scores or the need for other medical treatment, and six subjects were 426 enrolled in the study. The timeline of the study is presented in Figure 2. All subjects had baseline 427 MRI and PET-CT scans 1-4 months before the treatment. For treatment planning, acoustic 428 simulations were performed to estimate the skull-induced ultrasound attenuation and determine the 429 FUS transducer output for each patient. On the day of treatment, the patient underwent one session 430 of FUS sonication and post-treatment MRI was obtained approximately 2 h after the sonication to 431 assess BBBO and safety. We aimed to establish a safety baseline with a single treatment session 432 before introducing more complex protocols involving multiple sessions. Follow-up MRI scans were 433 acquired 3 days after sonication to confirm BBB reinstatement and safety. Two follow-up PET scans 434 were performed 3 weeks and 3 months after FUS for all subjects except Subject 1, who underwent 435 follow-up PET scans at 3 days and 5 months, respectively. A 3-month follow-up period was deemed 436 sufficient to evaluate acute and mid-term side effects, assuming that long-term adverse effects due 437 to FUS were unlikely to occur more than 3 months post treatment. A follow-up MMSE was 438 administered on the day of the 2nd follow-up PET. The timeline for each subject is listed in Table S6.

439 NgFUS System

We used a single-element 250-kHz FUS transducer (H-231, Sonic Concepts) with a central opening,
with guidance achieved using a neuronavigation system (Brainsight; Rogue Research) which was
first tested in NHPs [32–34]. The FUS device was cleared by the FDA through an investigational

device exemption (IDE G180140) for a first-in-human study at Columbia University. The -6 dB focal volume of the FUS beam was $6 \times 6 \times 49$ mm³ with an axially-elongated ellipsoidal shape. For cavitation monitoring, either a single-element transducer for subjects 1–4 (Figure S11A) or a multielement imaging array transducer for subject 5 and 6 (Figure S11B) was coaxially inserted in the central opening of the FUS transducer. A research ultrasound system (Vantage 256, Verasonics) was used for cavitation map acquisition. The transducer specifications and experimental parameters are listed in Table S7.

450 **Treatment Planning**

451 The target location was selected at an amyloid positive region in the right frontal lobe based on the 452 PET image. The initial FUS trajectory was determined by considering the focal size and the beam 453 incidence angle relative to the skull (Figure 3) for more efficient acoustic energy delivery [38]. 454 Patient-specific numerical simulations were employed for estimating the skull insertion loss of the 455 acoustic pressure using the k-wave toolbox [63,64] and MATLAB (Figure 3B). Heterogeneous maps 456 of the skull density and sound speed were obtained from the CT image acquired during screening 457 (resolution: 0.6×0.6×1 mm³, Biograph64 mCT, Siemens), where the maximum sound speed and 458 density were assumed to be c = 4000 m/s [65] and p = 1850 kg/m³ [66]. Skull absorption was also 459 modelled based on the CT image with a maximum absorption value of 0.68 dB/cm at the working 460 frequency, assuming a linear frequency dependency [66,67]. A 3-D acoustic pressure map was 461 obtained from the linear acoustic simulation with a grid size of $1 \times 1 \times 1$ mm³ (i.e., 6 points per wavelength) and a time step of 52.5 μ s. The insertion loss α was determined by $\alpha = 1 - P_{skull} / P_{freefield}$, 462 where P_{skull} is the maximum pressure within the brain obtained from a simulated acoustic map with 463 464 skull insertion and $P_{\text{freefield}}$ is the maximum pressure from a simulated map without the skull. More 465 than 35 simulations were performed per subject considering the transducer positioning deviations 466 (i.e., ± 10 mm in distance and $\pm 10^{\circ}$ in angular deviation). The trajectory was also adjusted to avoid 467 a large deviation of the insertion loss based on the simulation, and was used for FUS treatment as 468 the planned trajectory. The estimated insertion loss along the planned trajectory (Table 2) was used 469 for adjusting the sonication power to deliver the derated *in situ* pressure of 200 kPa.

470 **FUS Sonication**

The dimensions of the portable FUS system required patients to have partial hair shaving at the right frontal scalp for optimal acoustic coupling between the subject's head and the transducer (Figure

473 S1A). The subject's head was supported with the head and chin rest in a sitting position (Figure 3C), 474 and the anatomical registration to the neuronavigation system was performed based on the facial 475 landmarks (i.e., eves, ears, and nose). The chin and head rest was used for subjects 2, 4, 5, and 6. 476 The FUS transducer was positioned with the neuronavigation guidance to place the acoustic focus 477 at the planned target in the right frontal lobe (Figure 3D). We determined the sonication parameters 478 based on our previous simulations and pre-clinical studies [32,33]. The sonication parameters were 479 as follows: derated peak-negative pressure, 200 kPa; mechanical index (MI), 0.4; center frequency, 480 0.25 MHz; pulse length, 10 ms; pulse repetition frequency, 2 Hz. treatment duration, 2 min. 481 Microbubbles (0.1 mL/kg, Definity, Lantheus) were intravenously injected as a bolus starting at 3 s 482 and finishing at 10-20 s after the start of the sonication, and followed with a saline flush. 483 Approximately 50–75% of the microbubble bolus was introduced into circulation at the time of the 484 flush due to the dead space within the catheter tubing. During the sonication, the frequency spectrum 485 and cavitation dose were monitored (N=4), and the cavitation map with ultrasound B-mode image 486 was also employed for the last two subjects (N=2) (Figure 3E).

487 MRI and BBBO Quantification

488 Baseline (screening), post-FUS (day 0, 2 hr after FUS), and follow-up (day 3) MRI scans were 489 acquired (Figure 2) using a 3-T MRI system (Signa Premier, GE). Safety MR scans were obtained 490 during all three MRI sessions without any MR-contrast agent and included T2-weighted, T2-FLAIR, 491 and SWI with parameters shown in Table S8. T1-weighted images with the gadolinium contrast 492 agent (0.2 mL/kg, Dotarem[®]) were acquired for the confirmation of BBB opening and closing on 493 day 0 and day 3, respectively. The post-contrast T1-weighted MRI was obtained 15–20 min after the 494 gadolinium injection for increased sensitivity to detect BBBO [68,69]. BBBO on day 0 and closing 495 on day 3 were confirmed by a neuro-radiologist.

The contrast-enhanced volume was quantified by subtracting the day-3 post-contrast T1-weighted MRI from the day-0 post-contrast T1-weighted MRI and thresholding the subtracted image. The threshold was automatically selected so that the mean intensity within the opening volume is significantly greater than that of the surrounding region with a confidence level of 98% assuming the intensity of the subtracted image follows a Gaussian distribution [34]. Evaluation of BBBO by tissue types was performed using the brain segmentation methods described in the Supplementary Methods.

503 Blood Collection and Biomarker Measurement

504 Blood was collected from patients both prior to BBBO and 3 days post-BBBO to assess blood-based 505 Alzheimer's disease biomarker detection as a result of FUS from both serum and serum-derived 506 EVs. All subjects had blood drawn immediately 1-2 hours prior to the treatment (i.e., baseline) and 507 3 days after treatment. Serum was isolated after centrifugation of whole blood at 9.4 rcf for 5 min at 508 4 °C, and serum-derived EVs were isolated using an exosome precipitation solution according to the 509 manufacturer's published protocol (ExoQuick, Systems Biosciences, Palo Alto, CA). A Luminex 510 multiplex assay was used to quantify proteins in serum and in isolated serum-derived EVs (Luminex 511 Corp., Austin, TX). Single pro-cartaplex kits (ThermoFisher Scientific) were purchased and 512 combined to make a custom multiplex panel for analysis. The biomarker levels of subject 1 were not 513 acquired properly because of mishandling of the blood specimen.

514 **PET/CT**

515 PET/CT scans (CT: no contrast, axial plane, 4 mm section thickness, 4mm section interval) were acquired with a clinical PET scanner (Biograph64-mCT; Siemens) and with ¹⁸F-Florbetapir tracer 516 at 10mCi (Amyvid®; PETNET Solutions). PET/CT scans were acquired 32 to 107 days prior to 517 518 treatment, 3 to 29 days after treatment as the 1st follow-up time-point, and 82 to 164 days after 519 treatment as the 2nd follow-up time-point (Table S6). The A β load was quantified from PET scans 520 as SUVR, using the cerebellar GM as the reference region [70]. For region-specific amyloid analysis, 521 MRI and PET images were registered to the MNI space and automatically segmented by tissue types. 522 To investigate changes in A^β from a localized region at the site of BBBO to extended regions, three 523 areas were analyzed: BBBO volumes in the GM and WM (SUVR_{BBBO*}), the treated right frontal 524 lobe (SUVR_{FL}), and the treated right hemisphere (SUVR_H). The asymmetry SUVR (Asym.SUVR) 525 was measured by dividing the average SUVR in the treated region by that in the contralateral region 526 to monitor the relative progression of A β . Changes in SUVR and asymmetry at the 1st and 2nd 527 follow-ups compared to baseline were quantified (Figure 7). SUVR in Centiloid scale was calculated 528 using established methods [71–73], in order to allow standardized comparison with other studies. 529 Details of PET analysis are presented in the Supplementary Methods.

530 Cavitation Dose and Cavitation Mapping

For cavitation monitoring, PCD was used for subjects 1–4 and PAM was employed for subjects 5 and 6. Device specification and parameters are listed in Table S7. The CD was obtained from the 3rd to 6th harmonic/ultrahamonic frequencies. We computed the CD with harmonic (CD_h), ultraharmonic (CD_u), and broadband frequencies (CD_b) as described in the Supplementary Methods. The CCD was obtained by summing the normalized CD acquired after the microbubble flush and converting it to the logarithmic scale.

The cavitation map for each burst was reconstructed in real time from the 64-channel RF data by using the coherence-factor-based PAM implemented on a GPU (RTX A6000, NVIDIA). The final cavitation maps were obtained by averaging the acoustic energy maps for the bursts after the microbubble injection and masking them with the segmented brain volumes obtained from the MR images. More information on PAM implementation can be found in our previous study [34].

The BBBO volumes quantified in MR images were registered with the cavitation maps based on the tracked coordinate of the focus by the neuronavigation system and also based on ultrasound B-mode image that delineated the skin and skull; the registered B-mode (or cavitation map) and MRI slice are presented in Figure S12. We evaluated the predictive capability of each pixel in the cavitation image for detecting BBBO using the pixel-wise correlation. The AUC of ROC and PR curves were calculated following the methods described in our previous study [34].

548 **Targeting Accuracy and Precision**

549 The planned target/trajectory of FUS was determined in the planning step before treatment and the 550 treated target/trajectory was sampled during the FUS sonication on the neuronavigation system. 551 Transducer positioning errors were measured by the distance and angle differences between the 552 planned and treated target trajectories to assess the accuracy in the manual placement of the 553 transducer. To evaluate the targeting accuracy of BBBO, the Euclidean distance between the BBBO 554 centroid and the simulated focus was measured for each subject. The subject movement was obtained 555 from the tracked location of the FUS focus which was recorded over time during the sonication by 556 the neuronavigation system.

557 **Post Hoc Simulation**

558 During the retrospective analysis of data, we found that there was a registration error between CT 559 and MR volumes (1–7 mm). Additionally, there were differences between the treated trajectory for

- 560 sonication and the planned trajectory for the acoustic simulation before treatment, due to the
- 561 transducer positioning error. We re-simulated the acoustic pressure fields with the corrected
- 562 registration and the trajectory. The pressure field (Figure S7), attenuation, and derated peak pressure
- 563 (Table S5) were obtained with the corrected trajectory and registration. The derated peak pressure \hat{P}

564 was calculated by $\hat{P} = P/(1-\alpha) \cdot (1-\hat{\alpha})$ where P is 200 kPa and α and $\hat{\alpha}$ are the original and the

565 newly obtained insertion loss values, respectively.

566 Statistical Analysis

- 567 Statistical analysis was performed in MATLAB (Mathworks). Linear regression analysis was used
- 568 to evaluate the correlations of the CCDs (*N*=4), biomarker levels (*N*=5), asymmetry SUVR increase,
- and the simulated maximum pressure (N=5) with the contrast-enhanced volume, as well as the
- 570 correlation between the SUVR asymmetry and CCDs (*N*=4). R-squared and p values were obtained
- 571 from the regression for the statistical analysis. Pixel-wise correlation between the cavitation map
- and the BBBO was measured by the AUC of ROC curve and the AUC of PR curve after combining
- 573 data sets from subject 5 and 6, as described in the previous study [34]. MMSE scores of the subjects
- 574 were compared with those of ADNI subjects by using unpaired t-test. Changes in SUVR and the
- asymmetry between different time-points were analyzed using paired t-test.
- 576

577 Abbreviations

578	Αβ	Amyloid beta
579	AD	Alzheimer's disease
580	ADNI	Alzheimer's disease neuroimaging initiative
581	AE	Adverse event
582	BBB	Blood-brain barrier
583	BBBO	Blood-brain barrier opening
584	CCD	Cumulative cavitation dose
585	CGA-NPI	Caregiver-administered neuropsychiatric inventory
586	CT	Computed tomography
587	EV	Extracellular vesicle
588	FDA	U.S. Food and Drug Administration
589	FLAIR	Fluid-attenuated inversion recovery
590	FUS	Focused ultrasound
591	GM	Gray matter
592	GPU	Graphics processing unit
593	IRB	Institutional review board
594	MMSE	Mini-mental state examination
595	MRI	Magnetic resonance imaging

596	MR	Magnetic resonance
597	MRgFUS	Magnetic resonance-guided focused ultrasound
598	NHP	Non-human primate
599	NgFUS	Neuronavigation-guided FUS
600	PĂM	Passive acoustic mapping
601	PCD	Passive cavitation detection
602	PET	Positron emission tomography
603	PR	Precision-recall
604	ROC	Receiver operating characteristic
605	SAE	Adverse event
606	SUVR	Standard uptake value ratio
607	SUVR _{BBBO*}	Standard uptake value ratio measured within BBBO volume in the gray and white
608	matter	
609	SUVR _{FL}	Standard uptake value ratio measured within the treated frontal lobe
610	SUVR _H	Standard uptake value ratio measured within the treated hemisphere
611	SWI	Susceptibility-weighted imaging
612		

613 Acknowledgments

614 The authors wish to thank Maria F. Murillo, Alexander Berg, Rebecca L. Noel, and Nancy Kwon

- 615 for support and insightful discussion.
- 616

617 **Contributions**

- 618 ANP, EEK, and LSH initially developed the concept of the study;
- 619 SB, KL, RJ, SJG, OY, FNT, ANP, DK, LSH, and EEK conducted the FUS treatments;
- 620 LSH performed the neurological examinations;
- 621 SB processed and analyzed the cavitation, patient motion, and MRI data;
- 622 OY, KL, SJG, and FNT performed the numerical simulations;
- 623 KL and RJ processed and analyzed PET data;
- 624 AKS, AJB, SB, and FNT processed and analyzed blood biomarker data;
- 625 SB, RJ, SJG, KL, AJB, and EEK discussed and reviewed all the data;
- 626 KL, DK, ANP, and RJ assisted in patient recruitment;
- 627 ANP, KL, RJ, and SB prepared technical and regulatory documentation of the device;
- 628 EEK acquired funding and provided resources for the study as a principal investigator;
- 629 EEK and LSH supervised the clinical study;
- 630 SB wrote the original manuscript and visualized the data;
- 631 SB, KL, ANP, RJ, LSH, EEK, AJB, and SJG and edited the manuscript;

- 632 All authors reviewed and approved the final manuscript.
- 633

634 Competing interests

- 635 Some of the work presented herein is supported by patents optioned to Delsona Therapeutics, Inc.
- 636 where EEK serves as co-founder and scientific adviser. SB, ANP, RJ, KL, SJG, OY, FNT, DK,
- 637 AKS, AB, and LSH declare no conflict of interest.
- 638

639 **References**

- Alzheimer's Association. 2022 Alzheimer's disease facts and figures. Alzheimer's Dement.
 2022; 18: 1–118.
- Budd Haeberlein S, Aisen PS, Barkhof F, et al. Two randomized phase 3 studies of
 Aducanumab in early Alzheimer's disease. Journal of Prevention of Alzheimer's Disease.
 2022; 9: 197–210.
- van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in Early Alzheimer's Disease. Vol.
 388, The New England Journal of Medicine. Krause und Pachernegg GmbH; 2023.
- Mintun M, Solomon P, Sims JR, et al. Donanemab in early symptomatic Alzheimer's disease:
 Efficacy and safety in TRAILBLAZER-ALZ 2, a phase 3 randomized clinical trial. In:
 Alzheimer's Association International Conference. Amsterdam;
- 650 5. Pardridge WM. Treatment of Alzheimer's disease and blood-brain barrier drug delivery.
 651 Pharmaceuticals. 2020; 13: 1–25.
- 6. Banks WA, Terrell B, Farr SA, Robinson SM, Nonaka N, Morley JE. Passage of amyloid
 protein antibody across the blood-brain barrier in a mouse model of Alzheimer's disease. Vol.
 23, Peptides. 2002.
- Pandit R, Chen L, Götz J. The blood-brain barrier: Physiology and strategies for drug delivery.
 Adv Drug Deliv Rev. 2020; 165–166: 1–14.
- McMahon D, O'Reilly MA, Hynynen K. Therapeutic agent delivery across the blood-brain
 barrier using focused ultrasound. Annu Rev Biomed Eng. 2021; 23: 89–113.
- 659 9. Chen L, Cruz E, Oikari LE, Padmanabhan P, Song J, Götz J. Opportunities and challenges in
 660 delivering biologics for Alzheimer's disease by low-intensity ultrasound. Vol. 189, Advanced
 661 Drug Delivery Reviews. Elsevier B.V.; 2022.
- Konofagou EE. Optimization of the ultrasound-induced blood-brain barrier opening.
 Theranostics. 2012; 2: 1223–37.
- Chen H, Brayman AA, Kreider W, Bailey MR, Matula TJ. Observations of translation and
 jetting of ultrasound-activated microbubbles in mesenteric microvessels. Ultrasound Med
 Biol. 2011; 37: 2139–48.

- Kooiman K, Roovers S, Langeveld SAG, et al. Ultrasound-responsive cavitation nuclei for
 therapy and drug delivery. Ultrasound Med Biol. 2020; 46: 1296–325.
- Leinenga G, Bodea L, Schröder J, et al. Transcriptional signature in microglia isolated from
 an Alzheimer's disease mouse model treated with scanning ultrasound. Bioeng Transl Med.
 2023; 8: e10329.
- Karakatsani ME, Ji R, Murillo MF, et al. Focused ultrasound mitigates pathology and improves spatial memory in Alzheimer's mice and patients. Theranostics [Internet]. 2023; 13: 4102–20. Available at: https://www.thno.org/v13p4102.htm
- Kline-Schoder AR, Noel RL, Phatnani H, Menon V, Konofagou EE. Focused UltrasoundMediated Blood–Brain Barrier Opening Best Promotes Neuroimmunomodulation through
 Brain Macrophage Redistribution. Neuroglia. 2023; 4: 141–57.
- Lipsman N, Meng Y, Bethune AJ, et al. Blood-brain barrier opening in Alzheimer's disease
 using MR-guided focused ultrasound. Nat Commun. 2018; 9: 1–8.
- Park SH, Baik K, Jeon S, Chang WS, Ye BS, Chang JW. Extensive frontal focused ultrasound
 mediated blood-brain barrier opening for the treatment of Alzheimer's disease: a proof-ofconcept study. Transl Neurodegener. 2021; 10.
- Rezai AR, Ranjan M, Haut MW, et al. Focused ultrasound-mediated blood-brain barrier opening in Alzheimer's disease: long-term safety, imaging, and cognitive outcomes. J
 Neurosurg [Internet]. 2022; 139: 275–83. Available at: https://thejns.org/view/journals/j-neurosurg/aop/article-10.3171-2022.9.JNS221565/article-10.3171-2022.9.JNS221565.xml
- Meng Y, Goubran M, Rabin JS, et al. Blood-brain barrier opening of the default mode
 network in Alzheimer's disease with magnetic resonance-guided focused ultrasound. Brain.
 2023; 146: 865-72.
- Abrahao A, Meng Y, Llinas M, et al. First-in-human trial of blood–brain barrier opening in amyotrophic lateral sclerosis using MR-guided focused ultrasound. Nat Commun [Internet].
 2019; 10: 1–9. Available at: http://dx.doi.org/10.1038/s41467-019-12426-9
- 693 21. Gasca-Salas C, Fernández-Rodríguez B, Pineda-Pardo JA, et al. Blood-brain barrier opening
 694 with focused ultrasound in Parkinson's disease dementia. Nat Commun. 2021; 12.
- Mainprize T, Lipsman N, Huang Y, et al. Blood-brain barrier opening in primary brain tumors
 with non-invasive MR-guided focused ultrasound: A clinical safety and feasibility study. Sci
 Rep [Internet]. 2019; 9: 1–7. Available at: http://dx.doi.org/10.1038/s41598-018-36340-0
- Anastasiadis P, Gandhi D, Guo Y, et al. Localized blood-brain barrier opening in infiltrating
 gliomas with MRI-guided acoustic emissions-controlled focused ultrasound. Proc Natl Acad
 Sci U S A. 2021; 118.
- Meng Y, Reilly RM, Pezo RC, et al. MR-guided focused ultrasound enhances delivery of
 trastuzumab to Her2-positive brain metastases. Sci Transl Med. 2021; 13: eabj4011.
- D'Haese PF, Ranjan M, Song A, et al. β-Amyloid plaque reduction in the hippocampus after
 focused ultrasound-Induced blood–brain barrier opening in Alzheimer's disease. Front Hum
 Neurosci. 2020; 14.

- Rezai AR, D'Haese P-F, Finomore V, et al. Ultrasound blood-brain barrier opening and
 Aducanumab in Alzheimer's disease. New England Journal of Medicine [Internet]. 2024;
 390: 55–62. Available at: http://www.nejm.org/doi/10.1056/NEJMoa2308719
- 27. Epelbaum S, Burgos N, Canney M, et al. Pilot study of repeated blood-brain barrier disruption
 710 in patients with mild Alzheimer's disease with an implantable ultrasound device. Alzheimers
 711 Res Ther. 2022; 14.
- Jeong H, Song I-U, Chung Y-A, et al. Short-term efficacy of transcranial focused ultrasound to the hippocampus in Alzheimer's disease: A preliminary study. J Pers Med [Internet]. 2022;
 12: 250. Available at: https://www.mdpi.com/2075-4426/12/2/250
- Chen K-T, Chai W-Y, Lin C-J, et al. Neuronavigation-guided focused ultrasound for
 transcranial blood-brain barrier opening and immunostimulation in brain tumors. Sci Adv.
 2021; 7: eabd0772.
- Chen K-T, Lin Y-J, Chai W-Y, et al. Neuronavigation-guided focused ultrasound (NaviFUS)
 for transcranial blood-brain barrier opening in recurrent glioblastoma patients: clinical trial
 protocol. Ann Transl Med. 2020; 8: 673–673.
- Jeong H, Im JJ, Park JS, et al. A pilot clinical study of low-intensity transcranial focused ultrasound in Alzheimer's disease. Ultrasonography. 2021; 40: 512–9.
- Pouliopoulos AN, Wu SY, Burgess MT, Karakatsani ME, Kamimura HAS, Konofagou EE.
 A clinical system for non-invasive blood–brain barrier opening using a neuronavigationguided single-element focused ultrasound transducer. Ultrasound Med Biol. 2020; 46: 73–89.
- Pouliopoulos AN, Kwon N, Jensen G, et al. Safety evaluation of a clinical focused ultrasound
 system for neuronavigation guided blood-brain barrier opening in non-human primates. Sci
 Rep. 2021; 11: 15043.
- 34. Bae S, Liu K, Pouliopoulos AN, Ji R, Konofagou EE. Real-time passive acoustic mapping
 with enhanced spatial resolution in neuronavigation-guided focused ultrasound for bloodbrain barrier opening. IEEE Trans Biomed Eng. 2023; 70: 2874–85.
- Marchi N, Cavaglia M, Fazio V, Bhudia S, Hallene K, Janigro D. Peripheral markers of blood brain barrier damage. Vol. 342, Clinica Chimica Acta. 2004.
- Huang Y, Meng Y, Pople CB, et al. Cavitation feedback control of focused ultrasound bloodbrain barrier opening for drug delivery in patients with Parkinson's disease. Pharmaceutics
 [Internet]. 2022; 14: 2607. Available at: https://www.mdpi.com/1999-4923/14/12/2607
- 37. Wu SY, Sanchez CS, Samiotaki G, Buch A, Ferrera VP, Konofagou EE. Characterizing
 focused-ultrasound mediated drug delivery to the heterogeneous primate brain in vivo with
 acoustic monitoring. Sci Rep. 2016; 6.
- Karakatsani MEM, Samiotaki GM, Downs ME, Ferrera VP, Konofagou EE. Targeting effects
 on the volume of the focused ultrasound-Induced blood-brain barrier opening in nonhuman
 primates in vivo. IEEE Trans Ultrason Ferroelectr Freq Control. 2017; 64: 798–810.
- Fry FJ, Kossoff G, Eggleton RC, Dunn F. Threshold ultrasonic dosages for structural changes
 in the mammalian brain. J Acoust Soc Am. 1970; 48: 1413–7.

- Cavaglia M, Dombrowski SM, Drazba J, Vasanji A, Bokesch PM, Janigro D. Regional
 variation in brain capillary density and vascular response to ischemia. Brain Res. 2001; 910:
 81–93.
- McDannold N, Arvanitis CD, Vykhodtseva N, Livingstone MS. Temporary disruption of the
 blood-brain barrier by use of ultrasound and microbubbles: Safety and efficacy evaluation in
 rhesus macaques. Cancer Res. 2012; 72: 3652–63.
- 42. Zhou H, Liu Y, Long X, et al. Feasibility of ultrasound-induced blood-brain barrier disruption
 with a single-element transducer under three different frequencies in two non-human primates
 in vivo: Case report. J Neurosci Methods. 2022; 365.
- 43. Wardlaw JM, Benveniste H, Nedergaard M, et al. Perivascular spaces in the brain: anatomy,
 physiology and pathology. Nat Rev Neurol. 2020; 16: 137–53.
- Ye D, Chen S, Liu Y, et al. Mechanically manipulating glymphatic transport by ultrasound combined with microbubbles. Proc Natl Acad Sci U S A. 2023; 120.
- 45. Lee Y, Choi Y, Park EJ, et al. Improvement of glymphatic–lymphatic drainage of betaamyloid by focused ultrasound in Alzheimer's disease model. Sci Rep. 2020; 10.
- 46. Meng Y, Abrahao A, Heyn CC, et al. Glymphatics visualization after focused ultrasoundinduced blood-brain barrier opening in humans. Ann Neurol. 2019; 86: 975–80.
- 47. Mehta RI, Carpenter JS, Mehta RI, Haut MW, Ranjan M. Blood-brain barrier opening with
 MRI-guided focused ultrasound elicits meningeal venous permeability in humans with early
 Alzheimer disease. Radiology. 2021; 298: 645–62.
- 48. Ji R, Karakatsani ME, Burgess M, Smith M, Murillo MF, Konofagou EE. Cavitationmodulated inflammatory response following focused ultrasound blood-brain barrier opening.
 Journal of Controlled Release. 2021; 337: 458–71.
- Tung Y-S, Vlachos F, Feshitan JA, Borden MA, Konofagou EE. The mechanism of
 interaction between focused ultrasound and microbubbles in blood-brain barrier opening in
 mice. J Acoust Soc Am. 2011; 130: 3059–67.
- 50. Kamimura HAS, Flament J, Valette J, et al. Feedback control of microbubble cavitation for
 ultrasound-mediated blood-brain barrier disruption in non-human primates under magnetic
 resonance guidance. Journal of Cerebral Blood Flow and Metabolism. 2019; 39: 1191–203.
- 51. Lyka E, Coviello C, Kozick R, Coussios C-C. Sum-of-harmonics method for improved narrowband and broadband signal quantification during passive monitoring of ultrasound therapies. J Acoust Soc Am. 2016; 140: 741–54.
- 52. Sun T, Samiotaki G, Wang S, Acosta C, Chen CC, Konofagou EE. Acoustic cavitation-based
 monitoring of the reversibility and permeability of ultrasound-induced blood-brain barrier
 opening. Phys Med Biol. 2015; 60: 9079–94.
- Xu S, Ye D, Wan L, et al. Correlation between brain tissue damage and inertial cavitation
 dose quantified using passive cavitation imaging. Ultrasound Med Biol [Internet]. 2019; 45:
 2758–66. Available at: https://linkinghub.elsevier.com/retrieve/pii/S0301562919306945

- 54. O'Reilly MA, Hynynen K. Blood-brain barrier: Real-time feedback-controlled focused
 ultrasound disruption by using an acoustic emissions-based controller. Radiology. 2012; 263:
 96–106.
- Jones RM, McMahon D, Hynynen K. Ultrafast three-dimensional microbubble imaging in vivo predicts tissue damage volume distributions during nonthermal brain ablation.
 Theranostics. 2020; 10: 7211–30.
- 56. Song JH, Moldovan A, Prentice P. Non-linear acoustic emissions from therapeutically driven contrast agent microbubbles. Ultrasound Med Biol. 2019; 45: 2188–204.
- 57. Leinenga G, Götz J. Scanning ultrasound removes amyloid-β and restores memory in an
 Alzheimer's disease mouse model. Sci Transl Med. 2015; 7: 278ra33.
- 58. Burgess A, Dubey S, Yeung S, et al. Alzheimer disease in a mouse model: MR imagingguided focused ultrasound targeted to the hippocampus opens the blood-brain barrier and
 improves pathologic abnormalities and behavior. Radiology. 2014; 273: 736–45.
- Meng Y, Pople CB, Suppiah S, et al. MR-guided focused ultrasound liquid biopsy enriches circulating biomarkers in patients with brain tumors. Neuro Oncol. 2021; 23: 1789–97.
- Pacia CP, Yuan J, Yue Y, et al. Focused ultrasound–mediated liquid biopsy in a tauopathy
 mouse model. Radiology. 2023; 307.
- 800 61. Patel A, Schoen SJ, Arvanitis CD. Closed-loop spatial and temporal control of cavitation
 801 activity with passive acoustic mapping. IEEE Trans Biomed Eng. 2019; 66: 2022–31.
- 802 62. Jiménez-Gambín S, Jiménez N, Pouliopoulos A, Benlloch JM, Konofagou E, Camarena F.
 803 Acoustic holograms for bilateral blood-brain barrier opening in a mouse model. IEEE Trans
 804 Biomed Eng. 2022; 69: 1359–68.
- 805 63. Treeby BE, Cox BT. k-Wave: MATLAB toolbox for the simulation and reconstruction of
 806 photoacoustic wave fields. J Biomed Opt. 2010; 15: 021314.
- Treeby BE, Jaros J, Rendell AP, Cox BT. Modeling nonlinear ultrasound propagation in heterogeneous media with power law absorption using a k-space pseudospectral method. J
 Acoust Soc Am. 2012; 131: 4324–36.
- 810 65. Marsac L, Chauvet D, la Greca R, et al. Ex vivo optimisation of a heterogeneous speed of
 811 sound model of the human skull for non-invasive transcranial focused ultrasound at 1 MHz.
 812 International Journal of Hyperthermia. 2017; 33: 635–45.
- 813 66. Pinton G, Aubry JF, Bossy E, Muller M, Pernot M, Tanter M. Attenuation, scattering, and
 814 absorption of ultrasound in the skull bone. Med Phys. 2012; 39: 299–307.
- 815 67. Bossy E, Padilla F, Peyrin F, Laugier P. Three-dimensional simulation of ultrasound
 816 propagation through trabecular bone structures measured by synchrotron microtomography.
 817 Phys Med Biol. 2005; 50: 5545–56.
- 818 68. Israeli D, Tanne D, Daniels D, et al. The application of MRI for depiction of subtle blood
 819 brain barrier disruption in stroke. Int J Biol Sci [Internet]. 2011; 7: 1–8. Available at:
 820 http://www.biolsci.org1http://www.biolsci.org
- Bavies J, Siebenhandl-Wolff P, Tranquart F, Jones P, Evans P. Gadolinium:
 pharmacokinetics and toxicity in humans and laboratory animals following contrast agent

- administration. Vol. 96, Archives of Toxicology. Springer Science and Business Media
 Deutschland GmbH; 2022.
- 825 70. Landau SM, Fero A, Baker SL, et al. Measurement of longitudinal β-amyloid change with
 826 18F-florbetapir PET and standardized uptake value ratios. Journal of Nuclear Medicine. 2015;
 827 56: 567–74.
- Klein G, Delmar P, Voyle N, et al. Gantenerumab reduces amyloid-β plaques in patients with
 prodromal to moderate Alzheimer's disease: A PET substudy interim analysis. Vol. 11,
 Alzheimer's Research and Therapy. 2019.
- 831 72. Navitsky M, Joshi AD, Kennedy I, et al. Standardization of amyloid quantitation with
 832 florbetapir standardized uptake value ratios to the Centiloid scale. Alzheimer's and Dementia.
 833 2018; 14: 1565–71.
- Klunk WE, Koeppe RA, Price JC, et al. The Centiloid project: Standardizing quantitative
 amyloid plaque estimation by PET. Alzheimer's and Dementia [Internet]. 2015; 11: 1-15.e4.
 Available at: http://dx.doi.org/10.1016/j.jalz.2014.07.003
- 837
- 838

839

841 **Table**

842

843 Table I. Patient Characteristics

Subject#	I	2	3	4	5	6
Age range	70-74	80-84	65-69	65-69	55-59	70-74
Sex	F	Μ	F	F	Μ	F
MMSE	18	20	15	21	24	15
GDS	I	I	2	I	0	0
MHIS	I	0	2	I	0	I

844 MMSE: Mini-Mental State Examination on the day of screening, GDS: Geriatric Depression Scale on the day

845 of screening, MHIS: Modified Hachinski Ischemia Scale

846

848 **Table 2. Summary of the treatment.**

Subject #	I	2	3	4	5	6
Contrast-enhanced volume (mm ³)	2013	414	0	951	278	1262
Skull-induced attenuation*	0.84	0.72	0.75	0.72	0.7	0.75
Procedure time** (min)	-	38	47	21	36	35
Transducer positioning errors † (mm, °)	-	4.7, 11.2	5.3, 13.0	4.3, 7.0	8.2, 14.5	5.8, 10.5
Subject movements ^{††} (MAD, max) (mm)	-	-	2.3, 9.4	0.5, 1.5	0.25, 1.1	0.28, 0.96
Distance between the BBBO centroid	23.2	13.3	-	8.4	5.4	11.3
and the simulated focus‡ (mm)						

849 * Obtained by the acoustic simulation based on the planned target prior to the treatment.

850 ** Time duration for the subject sitting on the treatment chair; including anatomical registration for the 851 neuronavigation, targeting, sonication, and patient release.

[†]Distance (mm) and angle difference (°) between the planned trajectory and the actual trajectory during the
 treatment.

854 ⁺⁺ Subject movement was measured by the mean absolute deviation (MAD) from its centroid and the 855 maximum distance (max) from the initial location.

\$56 ‡ Distance between the centroid of the BBBO and the estimated focal position in the simulated pressure
 map

Table 3. Changes in SUVR and asymmetry SUVR at the 1st and 2nd follow-up compared to

860 **the baseline (mean±std)**

Region	∆SUVR		△Asym.SUVR			
	lst F/U	2nd F/U	lst F/U	2nd F/U		
BBBO*	-1.17±5.51, p=.66	5.05±7.20, p=.19	-1.67±5.09, p=.50	-0.68±1.05, p=.22		
FL	1.97±5.51, p=.47	6.95±6.51, p=.076	-1.00±1.12, p=.12	-1.47±0.77, p=.013		
Н	1.43±5.73, p=.61	6.80±5.88, p=.061	-0.64±0.65, p=.092	-0.90±0.26, p=.001		

861 SUVR: standard uptake value ratio, Asym.: asymmetry, BBBO*: blood-brain barrier opening in gray and white
 862 matter, FL: frontal lobe, H: hemisphere, F/U: follow-up.

863 The 1st F/U and 2nd F/Us were 20±9 days and 103±30 days after focused ultrasound treatment, respectively.

864 Mean and standard deviations were calculated from 5 subjects with BBBO.

866 Figure



868 Figure 1. Illustration of focused ultrasound (FUS)-induced blood-brain barrier (BBB) opening.

869 Systemically administered microbubbles oscillate under localized FUS and transiently open the BBB for drug

870 delivery or immune-stimulation at the targeted brain tissue. Oscillating microbubbles emit acoustic cavitation

signals which can be used for treatment monitoring.

872

	Month −4 to −1	Week −2 to Day −1	Day 0	Day 3	Day 3 to 28	Month 3 to 5	
			+				\rightarrow
	Baseline MRI	Simulation	Baseline Blood 1–2 h before FUS	Day 3 MRI	1 st f/u PET	2 nd f/u PET	
	Baseline PET-CT		FUS	Day 3 Blood		f/u MMSE	
873	Baseline MMSE		Day 0 MRI ^{1–3 h} after FUS				

- 874 Figure 2. Timeline of the clinical study
- 875



876

877 Figure 3. Portable NgFUS planning and treatment. (A) Selection of the target and the trajectory of 878 the FUS beam. (B) Acoustic pressure map (right) obtained from simulations using CT image (left) for skull 879 insertion loss estimation. (C) Subject undergoing the treatment session. The subject's head was supported 880 and fixed by a head and chin rest. The FUS transducer with a coaxial single-element transducer (N=4) or a 881 phased array transducer (N=2) was fixed with the metallic arm during the 2-min treatment. (D) Targeting 882 with the real-time feedback of the neuronavigator. (E) Real-time cavitation monitoring with the frequency 883 spectrum, cavitation dose, and cavitation energy map (color) with the B-mode image (grayscale) (from top 884 to bottom). With PCD monitoring, only the frequency spectrum and cavitation dose were obtained. With 885 PAM, a cavitation map was obtained as well as the spectrum and dose.



888 Figure 4. Blood-brain barrier (BBB) opening and closure confirmed by contrast-enhanced TI-889 weighted MRI. (A) Contrast enhancement indicating BBB opening in T_1 -weighted MRI 2 hours after 890 focused ultrasound (FUS) sonication. (B) Lack of contrast enhancement detected on follow-up T₁-weighted 891 MRI confirmed BBB reinstatement on day 3. (C, D) The 3-dimensional (3-D) reconstruction of the FUS 892 beam trajectory (blue line) and segmented contrast-enhanced volume (green) overlaid on the CT skull image 893 (gray) in (C) the sagittal and (D) the coronal view. The maximum pressure point of the focus is denoted as 894 a blue sphere on the blue line. The contrast-enhanced volume was well aligned with the FUS beam trajectory 895 for subjects 4–6. For subjects 1 and 2, the opening was aligned with the trajectory in the sagittal plane (C) 896 but approximately 10 mm off from the trajectory in the coronal plane (D). A video for 360° view of 3-D 897 volumes is available online as Supplementary Movie I.

medRxiv preprint doi: https://doi.org/10.1101/2023.12.21.23300222; this version posted May 6, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.



900 Harmonic, ultraharmonic, broadband cavitation doses (CDs) during the sonication. The CDs of subjects 1, 901 2, and 4 increased after the microbubble injection and flush and were sustained until the end of sonication. 902 In contrast, the CDs of subject 3, who did not exhibit successful BBBO, were unstable and exhibited a 903 sudden reduction at t = 90 s. The gray arrow indicates the moment of a sudden subject movement detected 904 (Supplementary Figure S7A). (B) Spectrograms displayed during the sonication showed the increased 905 cavitation signal in subjects 1, 2, and 4. Vertical dotted and dashed lines in (A) and (B) indicate the time of 906 the microbubble bolus injection and the subsequent saline flush, respectively. The amplitude in (B) was 907 normalized by the baseline broadband cavitation dose to better represent harmonic and ultraharmonic 908 components. (C) Positive correlation between the BBBO volume (i.e., contrast-enhanced volume) and the 909 cumulative CDs (CCDs) over time. (D) Cavitation map (color), which presents the distribution of acoustic 910 cavitation energy, is overlaid on the corresponding ultrasound B-mode image (gray) that shows the scalp 911 and the skull profiles. The brain region obtained from the registered MRI is marked as a blue line. (E) 912 Projected contrast-enhanced volume (color) overlaid on the MRI slice that is registered to the cavitation 913 map/B-mode image in (D). White dashed lines and ellipsoids in (D) and (E) show the focus of the FUS beam.

914

915

917



916 Figure 6. Correlation of blood-brain barrier opening (BBBO) volume and blood biomarker

918 with an increased log-fold change in biomarker concentration three days after treatment for (A) S100β in

levels on day 3 after neuronavigation-guided FUS (NgFUS). A larger BBBO volume is associated

919 serum, (B) Aβ42, (C) Aβ42/Aβ40, (D) GFAP, (E) Tau, and, (F) pT181 in extracellular vesicles.





921 Figure 7. Percent changes in the standard uptake value ratio (SUVR) and asymmetry SUVR 922 of 18F-Florbetapir and the correlation between the change in the asymmetry SUVR and the 923 cumulative cavitation dose (CCD). (A-C) Percent changes in SUVR within the blood-brain barrier 924 opening (BBBO) volume in the gray and white matter (Δ SUVR_{BBBO*}), the right frontal lobe (Δ SUVR_{FL}), and 925 the right hemisphere (Δ SUVR_H), at the 1st and the 2nd follow-ups compared to the baseline. (**D–F**) Percent 926 changes in asymmetry SUVR (Asym.SUVR) within the BBBO volume in the gray and white matter 927 $(\Delta Asym.SUVR_{BBBO*})$, the right frontal lobe $(\Delta Asym.SUVR_{FL})$, and the right hemisphere $(\Delta Asym.SUVR_{H})$ 928 compared to the baseline. Significant reduction in asymmetry values were found when measured within the 929 (E) frontal lobe and (F) hemisphere regions. p<0.05, p<0.01. (G) Linear correlation between the 930 Δ Asym.SUVR_{BBBO*} and the BBBO volume in the gray and white matter. (H) Linear correlations of 931 Δ Asym.SUVR_{BBBO*} with harmonic, ultraharmonic, broadband CCDs.